

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# Single Technology Appraisal

### Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

#### **Provisional Consultees Provisional Commentators (no right** to submit or appeal) General Company **Deciphera Pharmaceuticals** All Wales Therapeutics and **Toxicology Centre** (ripretinib) Allied Health Professionals Patient/carer groups Federation AMMF - The Cholangiocarcinoma • Board of Community Health Councils Charity in Wales Black Health Agency for Equality • British National Formulary Bladder and Bowel Community • Care Quality Commission **Bowel Cancer Information** • Department of Health - Northern • **Bowel Cancer UK** • Ireland Cancer Black Care Healthcare Improvement Scotland • Medicines and Healthcare products Cancer52 • • **Regulatory Agency GIST Cancer UK** • National Association of Primary Care Guts UK • • National Pharmacy Association Helen Rollason Cancer Charity • • NHS Confederation IA: Ileostomy and Internal Pouch • Scottish Medicines Consortium Association Independent Cancer Patients Voice Welsh Government • Macmillan Cancer Support Welsh Health Specialised Services • Committee Maggie's Centres • Marie Curie • Comparator companies Ochre • None **Oesophageal Patients Association** • **PAWS-GIST Clinic** • Relevant research groups • OG Support Bowel Research UK Sarcoma UK • • Cochrane Upper Gastrointestinal South Asian Health Foundation • and Pancreatic Diseases Group **Specialised Healthcare Alliance** • Foundation for Liver research • Tenovus Cancer Care GASTROCAN • Genomics England • Healthcare professional groups Institute of Cancer Research • Association of Cancer Physicians MRC Clinical Trials Unit • Association of Coloproctology of • National Institute for Health and • Great Britain and Ireland Care Research

## Final Stakeholder List

Final stakeholder list for the evaluation of Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496] Issue date: March 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 1 of 3

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland</li> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> <li>British Psychosocial Oncology Society</li> <li>British Sarcoma Group</li> <li>British Society of Gastroenterology</li> <li>Cancer Research UK</li> <li>Primary Care Society for Gastroenterology</li> <li>Royal College of General Practitioners</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Radiologists</li> <li>Royal College of Medicine</li> <li>Scottish Sarcoma Network</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul>	<ul> <li><u>Associated Public Health groups</u></li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> <li><u>Evidence Review Group</u></li> <li>National Institute for Health Research Health Technology Assessment Programme (NETSCC)</li> </ul>


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

# **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

# **Consultees**

Final stakeholder list for the evaluation of Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496] Issue date: March 2025 © National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 3



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.